Cargando…

Prolonged use of bedaquiline in the treatment for MDR-TB in a child

Bedaquiline (Bdq), a novel TB drug, is referred to the most effective drugs and used for the management of multidrug-resistant tuberculosis (MDR-TB). The drug produces a cardiotoxic effect, and its use is limited to six months. We describe a clinical observation of prolonged bedaquiline use in the t...

Descripción completa

Detalles Bibliográficos
Autores principales: Gubkina, Marina F., Khokhlova, Julia Yu., Yukhimenko, Natalia V., Petrakova, Irina Yu.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8551576/
https://www.ncbi.nlm.nih.gov/pubmed/34745886
http://dx.doi.org/10.1016/j.idcr.2021.e01311
_version_ 1784591189223145472
author Gubkina, Marina F.
Khokhlova, Julia Yu.
Yukhimenko, Natalia V.
Petrakova, Irina Yu.
author_facet Gubkina, Marina F.
Khokhlova, Julia Yu.
Yukhimenko, Natalia V.
Petrakova, Irina Yu.
author_sort Gubkina, Marina F.
collection PubMed
description Bedaquiline (Bdq), a novel TB drug, is referred to the most effective drugs and used for the management of multidrug-resistant tuberculosis (MDR-TB). The drug produces a cardiotoxic effect, and its use is limited to six months. We describe a clinical observation of prolonged bedaquiline use in the treatment for MDR-TB using a restricted number of drugs, to which susceptibility was preserved, in a 12-year-old child. The previous treatment course had failed; the patient remained sputum-positive after eight months of the treatment. We used a personalized approach to chemotherapy correction based on repeat drug susceptibility testing. The treatment regimen only contained those drugs, to which susceptibility was preserved: amikacin, cycloserine, linezolid, bedaquiline (AmCsLzdBdq). Amikacin was withdrawn after three months due to the development of sensorineural hearing loss. The treatment was continued with CsLzdBdq. The total chemotherapy course took 18 months. Sputum conversion was observed after one month, cavity closure – by 18 months of treatment. We did not observe cardiotoxic effects due to prolonged bedaquiline use. The administration of prolonged bedaquiline use was based on life-saving considerations. We achieved favourable treatment outcome and demonstrated safety of prolonged bedaquiline use for a child.
format Online
Article
Text
id pubmed-8551576
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-85515762021-11-04 Prolonged use of bedaquiline in the treatment for MDR-TB in a child Gubkina, Marina F. Khokhlova, Julia Yu. Yukhimenko, Natalia V. Petrakova, Irina Yu. IDCases Case Report Bedaquiline (Bdq), a novel TB drug, is referred to the most effective drugs and used for the management of multidrug-resistant tuberculosis (MDR-TB). The drug produces a cardiotoxic effect, and its use is limited to six months. We describe a clinical observation of prolonged bedaquiline use in the treatment for MDR-TB using a restricted number of drugs, to which susceptibility was preserved, in a 12-year-old child. The previous treatment course had failed; the patient remained sputum-positive after eight months of the treatment. We used a personalized approach to chemotherapy correction based on repeat drug susceptibility testing. The treatment regimen only contained those drugs, to which susceptibility was preserved: amikacin, cycloserine, linezolid, bedaquiline (AmCsLzdBdq). Amikacin was withdrawn after three months due to the development of sensorineural hearing loss. The treatment was continued with CsLzdBdq. The total chemotherapy course took 18 months. Sputum conversion was observed after one month, cavity closure – by 18 months of treatment. We did not observe cardiotoxic effects due to prolonged bedaquiline use. The administration of prolonged bedaquiline use was based on life-saving considerations. We achieved favourable treatment outcome and demonstrated safety of prolonged bedaquiline use for a child. Elsevier 2021-10-20 /pmc/articles/PMC8551576/ /pubmed/34745886 http://dx.doi.org/10.1016/j.idcr.2021.e01311 Text en © 2021 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Gubkina, Marina F.
Khokhlova, Julia Yu.
Yukhimenko, Natalia V.
Petrakova, Irina Yu.
Prolonged use of bedaquiline in the treatment for MDR-TB in a child
title Prolonged use of bedaquiline in the treatment for MDR-TB in a child
title_full Prolonged use of bedaquiline in the treatment for MDR-TB in a child
title_fullStr Prolonged use of bedaquiline in the treatment for MDR-TB in a child
title_full_unstemmed Prolonged use of bedaquiline in the treatment for MDR-TB in a child
title_short Prolonged use of bedaquiline in the treatment for MDR-TB in a child
title_sort prolonged use of bedaquiline in the treatment for mdr-tb in a child
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8551576/
https://www.ncbi.nlm.nih.gov/pubmed/34745886
http://dx.doi.org/10.1016/j.idcr.2021.e01311
work_keys_str_mv AT gubkinamarinaf prolongeduseofbedaquilineinthetreatmentformdrtbinachild
AT khokhlovajuliayu prolongeduseofbedaquilineinthetreatmentformdrtbinachild
AT yukhimenkonataliav prolongeduseofbedaquilineinthetreatmentformdrtbinachild
AT petrakovairinayu prolongeduseofbedaquilineinthetreatmentformdrtbinachild